Fear of cancer recurrence among survivors of childhood cancer

2020 ◽  
Vol 29 (7) ◽  
pp. 1132-1140 ◽  
Author(s):  
Hayley Wroot ◽  
Arfan R. Afzal ◽  
Caitlin Forbes ◽  
K. Brooke Russell ◽  
Lindsey Trepanier ◽  
...  
Keyword(s):  
Childhood Cancer ◽  
Cancer Recurrence ◽  
Fear Of Cancer Recurrence ◽  
Fear Of Cancer ◽  
Survivors Of Childhood Cancer

Fear of Cancer Recurrence Inventory--Danish Version

2018 ◽  
Author(s):  
Ida Hovdenak Jakobsen ◽  
Mette Moustgaard Jeppesen ◽  
Sébastien Simard ◽  
Henriette Vind Thaysen ◽  
Søren Laurberg ◽  
...  
Keyword(s):  
Cancer Recurrence ◽  
Fear Of Cancer Recurrence ◽  
Danish Version ◽  
Fear Of Cancer

Fear of Cancer Recurrence Questionnaire--Brief

2018 ◽  
Author(s):  
G. M. Humphris ◽  
E. Watson ◽  
M. Sharpe ◽  
G. Ozakinci
Keyword(s):  
Cancer Recurrence ◽  
Fear Of Cancer Recurrence ◽  
Fear Of Cancer

scholarly journals Perilla Oil and Bifidobacterium for Alleviating Fear of Cancer Recurrence in Breast Cancer Survivors: Study Protocol for a Three-Arm Phase II Randomized Controlled Study (POB Study)

2021 ◽  
Vol 4 (3) ◽  
pp. 46
Author(s):  
Yohei Sasaki ◽  
Mina Honyashiki ◽  
Takayuki Kinoshita ◽  
Akira Matsui ◽  
Ayako Nakashoji ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Phase Ii ◽  
Study Protocol ◽  
Breast Cancer Survivors ◽  
Cancer Recurrence ◽  
Fear Of Cancer Recurrence ◽  
Randomized Controlled ◽  
Perilla Oil ◽  
Fear Of Cancer

The fear of cancer recurrence (FCR) is the most common and most severe unmet need among cancer survivors. Safe treatments for the FCR that are easily disseminated are greatly needed. Our primary aim is a preliminary evaluation of the efficacy and effect size of perilla oil, which is rich in omega-3 fatty acids, and Bifidobacterium, a probiotic, on FCR in breast cancer survivors after the completion of chemotherapy. This study has been planned as an exploratory clinical study (phase II) and will be conducted as a three-arm, 12-week parallel group, masked-rater randomized controlled trial. Fifteen participants will be randomized with 1:1:1 allocation to receive Bifidobacterium plus perilla oil, Bifidobacterium alone, or no intervention (control). Interventions will end within 12 weeks after the random allocation of each participant. The participants will be outpatients with invasive breast cancer aged 20 years or older whose chemotherapy was completed at least 6 months before registration; hormone therapy may be ongoing. The primary outcome will be severity of FCR at 12 weeks assessed by masked raters using the 4-item Concerns about Recurrence Scale concerning overall fear of recurrence. The study protocol for the current study is registered in the Japan Registry of Clinical Trials (jRCTs031200029).

Sign in / Sign up

Export Citation Format

Share Document